Edesa Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Edesa Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Edesa Biotech Inc EDSA.OQ reported a quarterly adjusted loss of 60 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of four analysts for the quarter was for a loss of 58 cents per share. Wall Street expected results to range from -87 cents to -38 cents per share.
Reported revenue was zero; analysts expected zero.
Edesa Biotech Inc's reported EPS for the quarter was a loss of 60 cents.
The company reported a quarterly loss of $5.41 million.
Edesa Biotech Inc shares had fallen by 34.8% this quarter and gained 273.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 5.5% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Edesa Biotech Inc is $19.00, about 71.4% above its last closing price of $5.43
This summary was machine generated from LSEG data August 13 at 10:13 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.58 | -0.60 | Missed |
Mar. 31 2026 | -0.26 | -0.49 | Missed |
Dec. 31 2025 | -0.45 | -0.28 | Beat |
Sep. 30 2025 | -0.27 | -0.32 | Missed |